Gastric cancer drug resistance key “accomplice” was found

2022-07-24 0 By

The original title:Interleukin-1 receptor 1 (IL-1R1), a molecule previously thought to play a key role in chronic inflammation in gastric cancer, was found in a large sample of 795 gastric cancer patients in a multi-center study.It plays a key “accomplice” role in inducing local immunosuppression and therapeutic resistance of gastric cancer.At the same time, the study for the first time found that there was a close relationship between the expression level of IL-1R1 molecule and the treatment response of patients, so it can be used as a new cofactor to guide the individualized treatment of gastric cancer patients and a potential combination therapy target.The paper was published in the latest issue of the international academic journal Oncology Immunotherapy.Xu Jiejie introduces, gastric cancer is a kind of tumor that has high heterogeneity, there is great individual difference between different patients.Therefore, it is possible to achieve the best results only by taking individualized precision therapy.At present, the postoperative survival assessment of gastric cancer patients, the prediction of chemotherapy response and the selection of treatment options for patients insensitive to chemotherapy are the three major problems perplexing clinicians.In recent years, the rise of immunotherapy has provided a new strategy for the treatment of gastric cancer patients, but only 20% of patients with this therapy have an effect.Further analysis of tumor microenvironment, with a focus on the function of key molecules, is an urgent problem to be solved in the treatment of gastric cancer.In this study, we found that the high level of IL-1R1 in gastric cancer tissues is involved in the recruitment of macrophages associated with tumor progression, which inhibits immunity, and impairs the anti-tumor immune response of CD8+T cells in the gastric cancer microenvironment.Pbolizumab, an inhibitor of immune checkpoints targeting CD8+T cells, has no effect on patients with high IL-1R1 expression, that is, IL-1R1 promotes gastric cancer drug resistance by mediating immune escape from gastric cancer.Meanwhile, the effectiveness of chemotherapy drugs depends not only on their direct killing of cancer cells, but also on the reactivation of immune cells to help wipe out the remaining cancer cells. Patients with high EXPRESSION of IL-1R1 are also insensitive to adjuvant chemotherapy due to the lack of “supplementary” function of the immune system.Therefore, the response of patients to immune checkpoint inhibitor paprizizumab and chemotherapy drugs can be determined by detecting the expression level of IL-1R1 in tissue specimens of gastric cancer patients.This article by “original” original certification, the author of health Newspaper Co., LTD., visit Yuanben. IO query for authorization information.Statement: The copyright of this article belongs to the original author, if there is a source error or infringement of your legitimate rights and interests, you can contact us through email, we will deal with it in a timely manner.Email address: